Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer

Cell Death and Disease

Volumn 5, Issue 3, 2014, Pages

  Yang, F ^a,b   Deng, R ^a   Qian, X J ^a   Chang, S H ^c,d   Wu, X Q ^a   Qin, J ^a   Feng, G K ^a   Ding, K ^c,d   Zhu, X F ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^d UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

AKT inhibitor; Apoptosis; MAPK pathway; MTOR complexes; PI3K AKT pathway

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANTINEOPLASTIC AGENT; CALMODULIN; CASPASE 3; DC 120; EVEROLIMUS; INITIATION FACTOR 4E BINDING PROTEIN 1; IPATASERTIB; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; S6 KINASE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CANCER CELL; CANCER INHIBITION; CANCER SIZE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEEDBACK SYSTEM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RNA TRANSLATION; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CALCIUM SIGNALING; CALMODULIN; CELL PROLIFERATION; CLASS III PHOSPHATIDYLINOSITOL 3-KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEEDBACK, PHYSIOLOGICAL; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MULTIPROTEIN COMPLEXES; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-RAF; PYRIMIDINES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA INTERFERENCE; THIAZOLES; TIME FACTORS; TOR SERINE-THREONINE KINASES; TRANSFECTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897436663     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.43     Document Type: Article

References (53)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Mitsui H, Takuwa N, Maruyama T, Maekawa H, Hirayama M, Sawatari T et al. The MEK1-ERK map kinase pathway and the PI 3-kinase-Akt pathway independently mediate anti-apoptotic signals in HepG2 liver cancer cells. Int J Cancer 2001; 92: 55-62.
3. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999; 13: 2905-2927.
4. Calleja V, Alcor D, Laguerre M, Park J, Vojnovic B, Hemmings BA et al. Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo. PLoS Biol 2007; 5: e95.
5. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-1101.
6. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261-1274.
7. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110: 163-175.
8. Szado T, Vanderheyden V, Parys JB, De Smedt H, Rietdorf K, Kotelevets L et al. Phosphorylation of inositol 1,4,5-trisphosphate receptors by protein kinase B/Akt inhibits Ca2+ release and apoptosis. Proc Natl Acad Sci USA 2008; 105: 2427-2432.
9. Soulsby MD, Wojcikiewicz RJ. The type III inositol 1,4,5-trisphosphate receptor is phosphorylated by cAMP-dependent protein kinase at three sites. Biochem J 2005; 392: 493-497.
10. Han EK, Leverson JD, McGonigal T, Shah OJ, Woods KW, Hunter T et al. Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. Oncogene 2007; 26: 5655-5661.
11. Levy DS, Kahana JA, Kumar R. AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood 2009; 113: 1723-1729.
12. Lin J, Sampath D, Nannini MA, Lee BB, Degtyarev M, Oeh J et al. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin Cancer Res 2013; 19: 1760-1772.
13. Liu R, Liu D, Trink E, Bojdani E, Ning G, Xing M. The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway. J Clin Endocrinol Metab 2011; 96: E577-E585.
14. Li Z, Oh DY, Nakamura K, Thiele CJ. Perifosine-induced inhibition of akt attenuates brain-derived neurotrophic factor/TrkB-induced chemoresistance in neuroblastoma in vivo. Cancer 2011; 117: 5412-5422.
15. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14: 1351-1356.
16. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011; 19: 58-71.
17. Deng R, Yang F, Chang SH, Tang J, Qin J, Feng GK et al. DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth. Mol Pharmacol 2012; 82: 189-198.
18. Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R et al. Inhibitor hijacking of Akt activation. Nat Chem Biol 2009; 5: 484-493.
19. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009; 10: 307-318.
20. Sedrani R, Cottens S, Kallen J, Schuler W. Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant Proc 1998; 30: 2192-2194.
21. Choi J, Chen J, Schreiber SL, Clardy J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 1996; 273: 239-242.
22. Zhou HY, Huang SL. Current development of the second generation of mTOR inhibitors as anticancer agents. Chin J Cancer 2012; 31: 8-18.
23. Tretyn A, Kado RT, Kendrick RE. Loading and localization of Fluo-3 and Fluo-3/AM calcium indicators in sinapis alba root tissue. Folia Histochem Cytobiol 1997; 35: 41-51.
24. Thastrup O, Cullen PJ, Drobak BK, Hanley MR, Dawson AP. Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2+-ATPase. Proc Natl Acad Sci USA 1990; 87: 2466-2470.
25. Vergne I, Chua J, Deretic V. Tuberculosis toxin blocking phagosome maturation inhibits a novel Ca2+/calmodulin-PI3K hVPS34 cascade. J Exp Med 2003; 198: 653-659.
26. Kahl CR, Means AR. Regulation of cell cycle progression by calcium/ calmodulindependent pathways. Endocr Rev 2003; 24: 719-736.
27. Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999; 286: 1741-1744.
28. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998; 273: 18623-18632.
29. Heerding DA, Rhodes N, Leber JD, Clark TJ, Keenan RM, Lafrance LV et al. Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7- {[(3S)-3- piperidinylmethyl]oxy}-1H- imidazo[ 4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J Med Chem 2008; 51: 5663-5679.
30. Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA. Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res 2012; 18: 5816-5828.
31. Zinzalla V, Stracka D, Oppliger W, Hall MN. Activation of mTORC2 by association with the ribosome. Cell 2011; 144: 757-768.
32. Xie X, Guan KL. The ribosome and TORC2: collaborators for cell growth. Cell 2011; 144: 640-642.
33. Shah OJ, Hunter T. Turnover of the active fraction of IRS1 involves raptor- mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis. Mol Cell Biol 2006; 26: 6425-6434.
34. Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/ S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 2004; 14: 1650-1656.
35. Chauvin C, Koka V, Nouschi A, Mieulet V, Hoareau-Aveilla C, Dreazen A et al. Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program. Oncogene 2013; 33: 474-483.
36. Ma W, Mishra S, Gee K, Mishra JP, Nandan D, Reiner NE et al. Cyclosporin A and FK506 inhibit IL-12p40 production through the calmodulin/calmodulin- dependent protein kinaseactivated phosphoinositide 3-kinase in lipopolysaccharide- stimulated human monocytic cells. J Biol Chem 2007; 282: 13351-13362.
37. Yano S, Tokumitsu H, Soderling TR. Calcium promotes cell survival through CaM-K kinase activation of the protein-kinase-B pathway. Nature 1998; 396: 584-587.
38. Dann SG, Selvaraj A, Thomas G. mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol Med 2007; 13: 252-259.
39. Gulati P, Gaspers LD, Dann SG, Joaquin M, Nobukuni T, Natt F et al. Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34. Cell Metab 2008; 7: 456-465.
40. Karbowniczek M, Robertson GP, Henske EP. Rheb inhibits C-raf activity and B-raf/C-raf heterodimerization. J Biol Chem 2006; 281: 25447-25456.
41. Carriere A, Romeo Y, Acosta-Jaquez HA, Moreau J, Bonneil E, Thibault P et al. ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1). J Biol Chem 2011; 286: 567-577.
42. Winter JN, Jefferson LS, Kimball SR. ERK and Akt signaling pathways function through parallel mechanisms to promote mTORC1 signaling. Am J Physiol Cell Physiol 2011; 300: C1172-C1180.
43. Pal SK, Reckamp K, Yu H, Figlin RA. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 2010; 19: 1355-1366.
44. Liu L, Zhang CZ, Cai M, Fu J, Chen GG, Yun J. Downregulation of polo-like kinase 4 in hepatocellular carcinoma associates with poor prognosis. PLoS One 2012; 7: e41293.
45. Zhao JJ, Pan K, Li JJ, Chen YB, Chen JG, Lv L et al. Identification of LZAP as a new candidate tumor suppressor in hepatocellular carcinoma. PLoS One 2011; 6: e26608.
46. Xu S, Feng Z, Zhang M, Wu Y, Sang Y, Xu H et al. hSSB1 binds and protects p21 from ubiquitin-mediated degradation and positively correlates with p21 in human hepatocellular carcinomas. Oncogene 2011; 30: 2219-2229.
47. Deng R, Li W, Guan Z, Zhou JM, Wang Y, Mei YP et al. Acetylcholinesterase expression mediated by c-Jun-NH2-terminal kinase pathway during anticancer drug-induced apoptosis. Oncogene 2006; 25: 7070-7077.
48. Zhang XD, Borrow JM, Zhang XY, Nguyen T, Hersey P. Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene 2003; 22: 2869-2881.
49. Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini DM. Ragulator- Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 2010; 141: 290-303.
50. Yang WL, Wang J, Chan CH, Lee SW, Campos AD, Lamothe B et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 2009; 325: 1134-1138.
51. Sze KM, Wong KL, Chu GK, Lee JM, Yau TO, Ng IO. Loss of phosphatase and tensin homolog enhances cell invasion and migration through AKT/Sp-1 transcription factor/ matrix metalloproteinase 2 activation in hepatocellular carcinoma and has clinicopathologic significance. Hepatology 2011; 53: 1558-1569.
52. Deng R, Tang J, Ma JG, Chen SP, Xia LP, Zhou WJ et al. PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation. Oncogene 2011; 30: 944-955.
53. Nobukuni T, Joaquin M, Roccio M, Dann SG, Kim SY, Gulati P et al. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci USA 2005; 102: 14238-14243.